ESMO 2024: Regeneron’s melanoma combo therapy benefit continues beyond two years

Regeneron Pharmaceuticals’ investigational melanoma combination therapy shows continued response after two years in a Phase I trial.

The company presented longer-term data from the Phase I trial (NCT03005782) at the European Society for Medical Oncology (ESMO) Annual Meeting from 13 to 17 September.